Title

Effect of rifampicin combination-regimens against multi-drug resistant strains in North India

Authors

Misbahuddin M Rafeeq¹, Alaa Hamed Habib², Ahmad Alzamami³, Norah A. Alturki⁴, Mutaib M. Mashraqi⁵, Youssef Saeed Alghamdi⁶, Saleh Alshamrani⁵, Afaf Awwadh Alharthi⁷ & Suhail Ahmad^8,*

Affiliation

¹Department of Pharmacology, Faculty of Medicine, Rabigh, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; ²Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; ³Clinical Laboratory Science Department, College of Applied Medical Science, Shaqra University, AlQuwayiyah 11961, Saudi Arabia; ⁴Clinical Laboratory Science Department, College of Applied Medical Science, King Saud University, Riyadh 11433, Saudi Arabia; ⁵Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Najran University, Najran 61441, Saudi Arabia; ⁶Department of Biology, Turabah University College, Taif University, P.O.BOX 11099, Taif 21944, Saudi Arabia; ⁷College of Applied Medical Sciences, Department of Clinical Laboratory Sciences, Taif University, Taif, Saudi Arabia; ⁸Department of Bioengineering, Integral University, Lucknow, India; *Corresponding author

Email

Misbahuddin M Rafeeq - Email: marafeeq@kau.edu.sa

Alaa Hamed Habib - Email: ahabib@kau.edu.sa

Ahmad Alzamami - Email: aalzamami@su.edu.sa

Norah A Alturki - Email: noalturki@ksu.edu.sa

Mutaib M Mashraqi - Email: mmmashraqi@nu.edu.sa

Youssef Saeed Alghamdi - Email: ysghamdi@tu.edu.sa

Saleh Alshamrani - Email: saalshamrani@nu.edu.sa

Afaf Awwadh Alharthi - Email: a.awwadh@tu.edu.sa
Suhail Ahmad - Email: ssbiotechnologist@gmail.com & suhailamd@iul.ac.in

Article Type

Research Article

Date

Received April 2, 2022; Revised May 31, 2022; Accepted May 31, 2022, Published May 31, 2022

It is well-acknowledged that ‘combination therapy’ of antibiotics is indispensable for the treatment of patients suffering from serious bacterial infections. Therefore, it is of interest to collect data from the in vitro tests using ‘rifampicin-cefotaxime’ and ‘rifampicin-tetracycline’ combination regimens against multi drug resistant Escherichia coli and Klebsiella pneumoniae strains of nosocomial source in order to determine the effectiveness of the combination therapy. The minimum inhibitory concentration (MIC) values for cefotaxime, tetracycline and rifampicin antibiotics were found to be comparatively high for each of the antibiotics when given individually. However, carefully prepared combination-regimens exhibited significant inhibitory effect on the same bacterial isolates. DNA fragmentation study confirmed that ‘rifampicin-cefotaxime’ and ‘rifampicin-tetracycline’ combination-regimens could cause breakage of the bacterial DNA. Thus, we show that combination-regimens namely, ‘rifampicin-cefotaxime’ and ‘rifampicin-tetracycline’ were found to be capable of maintaining rifampicin susceptibility in the E. coli and K. pneumoniae strains. However, this susceptibility was not maintained by only rifampicin. More data using animal model experiments are needed for confirming and deriving translational benefits from these findings in future.

Keywords

Antibiotic combinations; Cefotaxime; DNA fragmentation assay; Escherichia coli

Citation

Rafeeq et al. Bioinformation 18(5): 482-487 (2022)

Edited by

P Kangueane

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.